Resolution phase lipid mediators of inflammation: Agonists of resolution

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 632-640

  Serhan, Charles N ^a   Chiang, Nan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 METHYLLIPOXIN A4; CD59 ANTIGEN; CIPROFLOXACIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LIPID; LIPOXIN A; LIPOXIN B; MARESIN 1; MICRORNA; PIOGLITAZONE; PLACEBO; RESOLVIN D1; RESOLVIN D2; RESOLVIN D3; RESOLVIN D4; RESOLVIN D5; RESOLVIN D6; RESOLVIN E1; RESOLVIN E2; RESOLVIN E3; RX 10045; SPECIALIZED PRO RESOLVING MEDIATORS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VANILLOID RECEPTOR 1;

AGGRESSIVE PERIODONTITIS; ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BACTERIAL CLEARANCE; CELL INFILTRATION; COLITIS; CYTOKINE PRODUCTION; DERMATITIS; DOSE RESPONSE; DRUG EFFICACY; DRY EYE; ECZEMA; ESCHERICHIA COLI INFECTION; EYE INFLAMMATION; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IC 50; INFLAMMATION; INFLAMMATORY PAIN; LEUKOCYTE; LEUKOCYTE MIGRATION; LIPIDOMICS; LOW DRUG DOSE; MACROPHAGE; MEMBRANE MICROPARTICLE; METABOLIC SYNDROME X; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PERITONITIS; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; STEREOCHEMISTRY; THROMBOSIS; ULCERATIVE COLITIS; URETER FIBROSIS; WOUND CLOSURE;

EID: 84885953361     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.012     Document Type: Review

References (80)

1. Majno G: Inflammation and infection: historic highlights. In Current Topics in Inflammation and Infection. Edited by Majno G, Cotran RS, Kaufman N. Williams & Wilkins; 1982:1-17.
2. Serhan CN: A search for endogenous mechanisms of antiinflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol 2004, 122:305-321. (Pubitemid 39506589)
3. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K: Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000, 192:1197-1204.
4. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 2002, 196:1025-1037. (Pubitemid 35231761)
5. Hong S, Gronert K, Devchand P, Moussignac R-L, Serhan CN: Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J Biol Chem 2003, 278:14677-14687. (Pubitemid 36799790)
6. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN: Neutrophilmediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest 1998, 101:819-826. (Pubitemid 28096079)
7. Bannenberg G, Serhan CN: Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010, 1801:1260-1273.
8. Serhan CN, Petasis NA: Resolvins and protectins in inflammation- resolution. Chem Rev 2011, 111:5922-5943.
9. Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA: Macrophage pro-resolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 2012, 26:1755-1765.
10. Chiang N, Fredman G, Bä ckhed F, Oh SF, Vickery TW, Schmidt BA, Serhan CN: Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012, 484:524-528.
11. Dalli J, Winkler JW, Colas RA, Arnardottir H, Cheng CYC, Chiang N, Petasis NA, Serhan CN: Resolvin D3 and aspirintriggered resolvin D3 are potent immunoresolvents. Chem Biol 2013, 20:188-201.
12. Serhan CN, Fredman G, Yang R, Karamnov S, Belayev LS, Bazan NG, Zhu M, Winkler JW, Petasis NA: Novel proresolving aspirin-triggered DHA pathway. Chem Biol 2011, 18:976-987.
13. Jones CN, Dalli J, Dimisko L, Wong E, Serhan CN, Irimia D: Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc Natl Acad Sci U S A 2012, 109:20560-20565.
14. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, Taguchi R, Masuda K, Sasaki K, Urabe D et al.: Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 2012, 287:10525-10534.
15. Isobe Y, Arita M, Iwamoto R, Urabe D, Todoroki H, Masuda K, Inoue M, Arai H: Stereochemical assignment and antiinflammatory properties of the omega-3 lipid mediator resolvin E3. J Biochem 2013 http://dx.doi.org/10.1093/jb/ mvs151.
16. Dalli J, Serhan CN: Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 2012, 120:e60-e72.
17. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN: Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 2011, 186:5543-5547.
18. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN: Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005, 201:713-722. (Pubitemid 40395117)
19. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN: Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007, 178:3912-3917. (Pubitemid 46417661)
20. Qu X, Zhang X, Yao J, Song J, Nikolic-Paterson DJ, Li J: Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol 2012 http://dx.doi.org/10.1002/path. 4050.
21. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee C-H, Yang R, Petasis NA, Serhan CN: Resolvin D1 binds human phagocytes with evidence for pro-resolving receptors. Proc Natl Acad Sci USA 2010, 107:1660-1665.
22. Marcheselli VL, Mukherjee PK, Arita M, Hong S, Antony R, Sheets K, Petasis N, Serhan CN, Bazan NG: Neuroprotectin D1/ protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot Essent Fatty Acids 2010, 82:27-34.
23. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN: Resolvin D1 receptor stereoselectivity and regulation of inflammation and pro-resolving microRNAs. Am J Pathol 2012, 180:2018-2027.
24. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M: Resolvin D1 limits polymorphonuclear leukocytes recruitment to inflammatory loci: receptor dependent actions. Arterioscler Thromb Vasc Biol 2012, 32:1970-1978.
25. Gao L, Faibish D, Fredman G, Herrera BS, Chiang N, Serhan CN, Van Dyke TE, Gyurko R: Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol 2013, 190:689-694.
26. Dartt DA, Hodges RR, Li D, Shatos MA, Lashkari K, Serhan CN: Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol 2011, 186:4455-4466.
27. de Paiva CS, Schwartz CE, Gjorstrup P, Pflugfelder SC: Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea 2012, 31:1299-1303.
28. Rajasagi NK, Reddy PBJ, Suryawanshi A, Mulik S, Gjorstrup P, Rouse BT: Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J Immunol 2011, 186:1735-1746.
29. Wang SB, Hu KM, Seamon KJ, Mani V, Chen Y, Gronert K: Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. FASEB J 2012, 26:1506-1516.
30. Science Blog: Resolvyx announces positive data - Phase 2 trial of resolvin RX-10045 for dry eye syndrome. 2009 http://www.scienceblog.com.
31. Odusanwo O, Chinthamani S, McCall A, Duffey ME, Baker OJ: Resolvin D1 prevents TNF-alpha-mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol 2012, 302:C1331-C1345.
32. Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE: Impaired phagocytosis in localized aggressive periodontitis: rescue by resolvin E1. PLoS ONE 2011, 6:e24422.
33. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD: Resolvin E1 regulates interleukin-23, interferon-gamma and lipoxin A4 to promote resolution of allergic airway inflammation. Nat Immunol 2008, 9:873-879.
34. Haworth O, Cernadas M, Levy BD: NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J Immunol 2011, 186:6129-6135.
35. Rogerio AP, Haworth O, Croze R, Oh SF, Uddin M, Carlo T, Pfeffer MA, Priluck R, Serhan CN, Levy BD: Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J Immunol 2012, 189:1983-1991.
36. Eickmeier O, Seki H, Haworth O, Hilberath JN, Gao F, Uddin M, Croze RH, Carlo T, Pfeffer MA, Levy BD: Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 2012 http://dx.doi.org/10.1038/mi.2012.66.
37. Hudert CA, Weylandt KH, Wang J, Lu Y, Hong S, Dignass A, Serhan CN, Kang JX: Transgenic mice rich in endogenous n-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006, 103:11276-11281. (Pubitemid 44156509)
38. Bilal S, Haworth O, Wu L, Weylandt KH, Levy BD, Kang JX: Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. Biochim Biophys Acta 2011, 1812:1164-1169.
39. Miyata J, Fukunaga K, Iwamoto R, Isobe Y, Niimi K, Takamiya R, Takihara T, Tomomatsu K, Suzuki Y, Oguma T et al.: Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J Allergy Clin Immunol 2012 http://dx.doi.org/10.1016/j.jaci.2012.1007.1048.
40. Xu Z-Z, Zhang L, Liu T, Park J-Y, Berta T, Yang R, Serhan CN, Ji RR: Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 2010, 16:592-597.
41. Huang L, Wang C-F, Serhan CN, Strichartz G: Enduring prevention and transient reduction of post-operative pain by intrathecal resolvin D1. Pain 2011, 152:557-565.
42. Xu ZZ, Berta T, Ji RR: Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. J Neuroimmune Pharmacol 2012 http://dx.doi.org/10.1007/s11481-012-9394-8.
43. Quan-Xin F, Fan F, Xiang-Ying F, Shu-Jun L, Shi-Qi W, Zhao- Xu L, Xu-Jie Z, Qing-Chuan Z, Wei W: Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn. BMC Gastroenterol 2012, 12:148.
44. Park CK, Lü N, Xu ZZ, Liu T, Serhan CN, Ji RR: Resolving TRPV1 and TNF-a-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci 2011, 31:15072-15085.
45. Bang S, Yoo S, Yang TJ, Cho H, Hwang SW: 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br J Pharmacol 2012, 165:683-692.
46. Lima-Garcia J, Dutra R, da Silva K, Motta E, Campos M, Calixto J: The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvantinduced arthritis in rats. Br J Pharmacol 2011, 164:278-293.
47. Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, Mahanian M, Weitzman R, Hayden E, Rosenthal MJ et al.: 1alpha,25-Dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in alzheimer's disease patients. J Alzheimers Dis 2012 http://dx.doi.org/10.3233/JAD-121735.
48. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, La Cava A, Wiedau-Pazos M: Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis 2012, 1:60-74.
49. Bohr S, Patel SJ, Sarin D, Irimia D, Yarmush ML, Berthiaume F: Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen 2013, 21:35-43.
50. Kim TH, Kim GD, Jin YH, Park YS, Park CS: Omega-3 fatty acidderived mediator. Resolvin E1, ameliorates 2,4- dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int Immunopharmacol 2012, 14:384-391.
51. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L: Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol 2013, 168:172-178.
52. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN: Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005, 102:7671-7676. (Pubitemid 40741029)
53. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB: Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 2011, 187:1957-1969.
54. Titos E, Rius B, González-Périz A, López-Vicario C, Morán- Salvador E, Mart?́nez-Clemente M, Arroyo V, Clária J: Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by elicitying macrophage polarization toward a pro-resolving phenotype. J Immunol 2011, 187:5408-5418.
55. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M: Resolvin D1 decreases adipose tissue macrophage accumulation and imiproves insulin sensitivity in obese-diabetic mice. FASEB J 2011, 25:2399-2407.
56. Borgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C: Lipoxin A4 attenuates adipose inflammation. FASEB J 2012, 26:4287-4294.
57. Tang Y, Zhang MJ, Hellmann J, Kosuri M, Bhatnagar A, Spite M: Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 2013, 62:618-627.
58. Recchiuti A, Krishnamoorthy S, Fredman G, Chiang N, Serhan CN: MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J 2011, 25:544-560.
59. Fredman G, Li Y, Dalli J, Chiang N, Serhan CN: Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci Rep 2012, 2:639.
60. Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:869-874. (Pubitemid 46920139)
61. Samuelsson B: Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem 2012, 287:10070-10080.
62. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN: Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1291.
63. Rodriguez AR, Spur BW: Total synthesis of the macrophage derived anti-inflammatory lipid mediator Maresin 1. Tetrahedron Lett 2012, 53:4169-4172.
64. Rodriguez AR, Spur BW: First total synthesis of the antiinflammatory lipid mediator Resolvin D6. Tetrahedron Lett 2012, 53:86-89.
65. Rodriguez AR, Spur BW: Total synthesis of the antiinflammatory lipid mediator Resolvin E2. Tetrahedron Lett 2012, 53:1912-1915.
66. Ogawa N, Kobayashi Y: Total synthesis of the antiinflammatory and proresolving protectin D1. Tetrahedron Lett 2011, 52:3001-3004.
67. Ogawa S, Urabe D, Yokokura Y, Arai H, Arita M, Inoue M: Total synthesis and bioactivity of resolvin E2. Org Lett 2009, 11:3602-3605.
68. Ogawa N, Kobayashi Y: Total synthesis of resolvin E1. Tetrahedron Lett 2009, 50:6079-6082.
69. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN: Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 2010, 285:3451-3461.
70. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN: Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 2011, 121:569-581.
71. Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN: Resolvin E2 formation and impact in inflammation resolution. J Immunol 2012, 188:4527-4534.
72. Vong L, Ferraz JG, Dufton N, Panaccione R, Beck PL, Sherman PM, Perretti M, Wallace JL: Up-regulation of Annexin- A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS ONE 2012, 7:e39244.
73. Gutierrez AD, Sathyanarayana P, Konduru S, Ye Y, Birnbaum Y, Bajaj M: The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis 2012, 223:204-208.
74. Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, Serhan CN, Mayboroda OA: Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta 2012, 1821:1415-1424.
75. Yamaguchi H, Higashi N, Mita H, Ono E, Komase Y, Nakagawa T, Miyazawa T, Akiyama K, Taniguchi M: Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirinintolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 2011, 41:1711-1718.
76. Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, Creager MA, Serhan CN, Conte MS: Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 2010, 177:2116-2123.
77. Clària J, Dalli J, Yacoubian S, Gao F, Serhan CN: Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol 2012, 189:2597-2605.
78. Mas E, Croft KD, Zahra P, Barden A, Mori TA: Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 2012, 58:1476-1484.
79. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B et al.: The human serum metabolome. PLoS ONE 2011, 6:e16957.
80. Yanes O, Clark J, Wong DM, Patti GG, Sánchez-Ruiz A, Benton HP, Trauger SA, Desponts C, Ding S, Siuzdak G: Metabolic oxidation regulates embryonic stem cell differentiation. Nat Chem Biol 2010, 6:411-417.